Biomarkers for Lung Cancer Screening and Detection

Edwin J. Ostrin, David Sidransky, Avrum Spira, Samir M. Hanash

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Lung cancer is the leading worldwide cause of cancer mortality, as it is often detected at an advanced stage. Since 2011, low-dose CT scan-based screening has promised a 20% reduction in lung cancer mortality. However, effectiveness of screening has been limited by eligibility only for a high-risk population of heavy smokers and a large number of false positives generated by CT. Biomarkers have tremendous potential to improve early detection of lung cancer by refining lung cancer risk, stratifying positive CT scans, and categorizing intermediate-risk pulmonary nodules. Three biomarker tests (Early CDT-Lung, Nodify XL2, Percepta) have undergone extensive validation and are available to the clinician. The authors discuss these tests, with their clinical applicability and limitations, current ongoing evaluation, and future directions for biomarkers in lung cancer screening and detection.

Original languageEnglish (US)
Pages (from-to)2411-2415
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Issue number12
StatePublished - Dec 2020

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Biomarkers for Lung Cancer Screening and Detection'. Together they form a unique fingerprint.

Cite this